158 related articles for article (PubMed ID: 33598783)
1. Adoptive cell therapy of patient-derived renal cell carcinoma xenograft model with IL-15-induced γδT cells.
Zhang B; Li H; Liu W; Tian H; Li L; Gao C; Zheng J
Med Oncol; 2021 Feb; 38(3):30. PubMed ID: 33598783
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II study of adoptive transfer of γδ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma.
Kobayashi H; Tanaka Y; Yagi J; Minato N; Tanabe K
Cancer Immunol Immunother; 2011 Aug; 60(8):1075-84. PubMed ID: 21519826
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy for human renal cell carcinoma by adoptive transfer of autologous transforming growth factor beta-insensitive CD8+ T cells.
Wang L; Wen W; Yuan J; Helfand B; Li Y; Shi C; Tian F; Zheng J; Wang F; Chen L; Liang L; Zhou L; Lee C; Chen Z; Guo Y; Wang H; Zhang Q; Qin W
Clin Cancer Res; 2010 Jan; 16(1):164-73. PubMed ID: 20028741
[TBL] [Abstract][Full Text] [Related]
4. Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study.
Kobayashi H; Tanaka Y; Yagi J; Osaka Y; Nakazawa H; Uchiyama T; Minato N; Toma H
Cancer Immunol Immunother; 2007 Apr; 56(4):469-76. PubMed ID: 16850345
[TBL] [Abstract][Full Text] [Related]
5. Effect of 4,5-diazafluorene derivative on γδ T cell-mediated cytotoxicity against renal cell carcinoma.
Wen X; Wu Y; Tanaka Y; Awadasseid A; Tao H; Zhang W
Life Sci; 2021 Mar; 269():119066. PubMed ID: 33460663
[TBL] [Abstract][Full Text] [Related]
6. Questionable relevance of gamma delta T lymphocytes in renal cell carcinoma.
Inman BA; Frigola X; Harris KJ; Kuntz SM; Lohse CM; Leibovich BC; Kwon ED
J Immunol; 2008 Mar; 180(5):3578-84. PubMed ID: 18292585
[TBL] [Abstract][Full Text] [Related]
7. Complete remission of lung metastasis following adoptive immunotherapy using activated autologous gammadelta T-cells in a patient with renal cell carcinoma.
Kobayashi H; Tanaka Y; Shimmura H; Minato N; Tanabe K
Anticancer Res; 2010 Feb; 30(2):575-9. PubMed ID: 20332473
[TBL] [Abstract][Full Text] [Related]
8. Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma.
Bennouna J; Bompas E; Neidhardt EM; Rolland F; Philip I; Galéa C; Salot S; Saiagh S; Audrain M; Rimbert M; Lafaye-de Micheaux S; Tiollier J; Négrier S
Cancer Immunol Immunother; 2008 Nov; 57(11):1599-609. PubMed ID: 18301889
[TBL] [Abstract][Full Text] [Related]
9. IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human V gamma 9V delta 2 T cells for adoptive immunotherapy.
Thedrez A; Harly C; Morice A; Salot S; Bonneville M; Scotet E
J Immunol; 2009 Mar; 182(6):3423-31. PubMed ID: 19265120
[TBL] [Abstract][Full Text] [Related]
10. Adoptive immunotherapy of lung cancer with immobilized anti-TCRgammadelta antibody-expanded human gammadelta T-cells in peripheral blood.
Kang N; Zhou J; Zhang T; Wang L; Lu F; Cui Y; Cui L; He W
Cancer Biol Ther; 2009 Aug; 8(16):1540-9. PubMed ID: 19471115
[TBL] [Abstract][Full Text] [Related]
11. Ex Vivo Expanded Human Vγ9Vδ2 T-Cells Can Suppress Epithelial Ovarian Cancer Cell Growth.
Mao TL; Miao CH; Liao YJ; Chen YJ; Yeh CY; Liu CL
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30845699
[TBL] [Abstract][Full Text] [Related]
12. Zoledronate sensitizes neuroblastoma-derived tumor-initiating cells to cytolysis mediated by human γδ T cells.
Nishio N; Fujita M; Tanaka Y; Maki H; Zhang R; Hirosawa T; Demachi-Okamura A; Uemura Y; Taguchi O; Takahashi Y; Kojima S; Kuzushima K
J Immunother; 2012 Oct; 35(8):598-606. PubMed ID: 22996365
[TBL] [Abstract][Full Text] [Related]
13. T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy.
Leisegang M; Turqueti-Neves A; Engels B; Blankenstein T; Schendel DJ; Uckert W; Noessner E
Clin Cancer Res; 2010 Apr; 16(8):2333-43. PubMed ID: 20371691
[TBL] [Abstract][Full Text] [Related]
14. Preclinical evaluation of adoptive cell therapy for patients with metastatic renal cell carcinoma.
Markel G; Cohen-Sinai T; Besser MJ; Oved K; Itzhaki O; Seidman R; Fridman E; Treves AJ; Keisari Y; Dotan Z; Ramon J; Schachter J
Anticancer Res; 2009 Jan; 29(1):145-54. PubMed ID: 19331144
[TBL] [Abstract][Full Text] [Related]
15. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
16. T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma-Implications for Adoptive Cell Therapy.
Andersen R; Westergaard MCW; Kjeldsen JW; Müller A; Pedersen NW; Hadrup SR; Met Ö; Seliger B; Kromann-Andersen B; Hasselager T; Donia M; Svane IM
Cancer Immunol Res; 2018 Feb; 6(2):222-235. PubMed ID: 29301752
[No Abstract] [Full Text] [Related]
17. Human renal carcinoma line transfected with interleukin-2 and/or interferon alpha gene(s): implications for live cancer vaccines.
Belldegrun A; Tso CL; Sakata T; Duckett T; Brunda MJ; Barsky SH; Chai J; Kaboo R; Lavey RS; McBride WH
J Natl Cancer Inst; 1993 Feb; 85(3):207-16. PubMed ID: 8423625
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of allogeneic CD3AK cells on transplanted human renal cell cancer in mice with severe combined immune deficiency.
Ge L; Shan Z; Han Q; Zhang N; Zhao Y
J BUON; 2016; 21(2):399-406. PubMed ID: 27273950
[TBL] [Abstract][Full Text] [Related]
19. Synergistic effects of low‑dose chemotherapy and T cells in renal cell carcinoma.
Xu DD; Ding M; Tong P; Chong YY; Gu WY; Li Y; Fang XJ; Li N
Oncol Rep; 2020 Sep; 44(3):897-908. PubMed ID: 32705278
[TBL] [Abstract][Full Text] [Related]
20. Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma.
Viey E; Fromont G; Escudier B; Morel Y; Da Rocha S; Chouaib S; Caignard A
J Immunol; 2005 Feb; 174(3):1338-47. PubMed ID: 15661891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
